DelveInsight’s, “Acute Myeloid Leukemia (AML) - Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Acute Myeloid Leukemia (AML) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Acute Myeloid Leukemia (AML): Overview
Acute Myeloid Leukemia (AML) (AML) starts in the bone marrow (the soft inner part of certain bones, where new blood cells are made), but most often it quickly moves into the blood, as well. It can sometimes spread to other parts of the body including the lymph nodes, liver, spleen, central nervous system (brain and spinal cord), and testicles. Most often, AML develops from cells that would turn into white blood cells (other than lymphocytes), but sometimes AML develops in other types of blood-forming cells. Acute Myeloid Leukemia (AML) (AML) has many other names, including acute myelocytic leukemia, acute myelogenous leukemia, acute granulocytic leukemia, and acute non-lymphocytic leukemia.
"Acute Myeloid Leukemia (AML) - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute Myeloid Leukemia (AML) pipeline landscape is provided which includes the disease overview and Acute Myeloid Leukemia (AML) treatment guidelines. The assessment part of the report embraces, in depth Acute Myeloid Leukemia (AML) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Myeloid Leukemia (AML) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Acute Myeloid Leukemia (AML) R&D. The therapies under development are focused on novel approaches to treat/improve Acute Myeloid Leukemia (AML).
This segment of the Acute Myeloid Leukemia (AML) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Acute Myeloid Leukemia (AML) Emerging Drugs
BST-236: BioSight
Aspacytarabine (BST-236) is a novel proprietary anti-metabolite. It is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine, enabling delivery of high cytarabine doses to leukemia patients with lower systemic exposure to the free drug. The drug is currently in phase 2 of clinical trials for the treatment of Acute Myeloid Leukemia (AML).
Uproleselan: GlycoMimetics
GlycoMimetics is developing uproleselan, a specific E-selectin antagonist, to be used in combination with chemotherapy to treat patients with Acute Myeloid Leukemia (AML) (AML) and potentially other hematologic cancers. The drug is currently in phase 3 of clinical trials for the treatment of Acute Myeloid Leukemia (AML).
Sabatolimab: Novartis
Sabatolimab is an anti T-cell immunoglobulin and mucin domain 3 (anti-TIM3) monoclonal antibody being developed by Novartis. The drug is currently in phase 2 of clinical trials for the treatment of Acute Myeloid Leukemia (AML).
Pevonedistat: Takeda
Pevonedistat is a first in class NEDD8-activating enzyme (NAE) inhibitor. In pre-clinical studies, the inhibition of NAE by pevonedistat blocked the modification of select proteins, which resulted in disruption of cell cycle progression and cell survival, leading to cancer cell death. The drug is currently in phase 3 of clinical trials for the treatment of Acute Myeloid Leukemia (AML).
Further product details are provided in the report……..
This segment of the report provides insights about the different Acute Myeloid Leukemia (AML) drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 100+ key companies which are developing the therapies for Acute Myeloid Leukemia (AML). The companies which have their Acute Myeloid Leukemia (AML) drug candidates in the most advanced stage, i.e. phase III include, GlycoMimetics.
DelveInsight’s report covers around 100+ products under different phases of clinical development like
Acute Myeloid Leukemia (AML) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute Myeloid Leukemia (AML) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Myeloid Leukemia (AML) drugs.
Current Treatment Scenario and Emerging Therapies:
Introduction
Executive Summary
Acute Myeloid Leukemia (AML): Overview
Pipeline Therapeutics
Therapeutic Assessment
Acute Myeloid Leukemia (AML) – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Acute Myeloid Leukemia (AML) Collaboration Deals
Late Stage Products (Phase III)
Uproleselan: GlycoMimetics
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
BST-236: BioSight
Drug profiles in the detailed report…..
Inactive Products
Acute Myeloid Leukemia (AML) Key Companies
Acute Myeloid Leukemia (AML) Key Products
Acute Myeloid Leukemia (AML)- Unmet Needs
Acute Myeloid Leukemia (AML)- Market Drivers and Barriers
Acute Myeloid Leukemia (AML)- Future Perspectives and Conclusion
Acute Myeloid Leukemia (AML) Analyst Views
Acute Myeloid Leukemia (AML) Key Companies
Appendix
List of Table
Table 1: Total Products for Acute Myeloid Leukemia (AML)
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Acute Myeloid Leukemia (AML)
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• BioSight
• GlycoMimetics
• Novartis
• Takeda
• Menarini Group
• ImmunoGen
• Kartos Therapeutics
• Plexxikon
• Shijiazhuang Yiling Pharmaceutical
• Oscotec
• Ryvu Therapeutics
• Aptose Biosciences
• Innovent Biologics
• JW Pharmaceutical
• Hanmi Pharmaceutical
• GEMoaB Monoclonals
• ALX Oncology
• I-Mab Biopharma
• DCPrime BV
• Amgen
• Synimmune GmbH
• BioTheryX
• Celyad Oncology
• Cleave Therapeutics
• Astex Pharmaceuticals
• Amphivena Therapeutics
